1623 - Prophylaxis of neutropenia during adjuvant DAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy with dicarbamin in patients with early breast...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Breast Cancer, Early Stage
Complications of Treatment
Supportive Care
Presenter Mikhail Kopp
Authors M.V. Kopp1, I.A. Koroleva1, L.V. Shaplygin2, A.S. Machalova1
  • 1Chemotherapy, Samara Regional Clinical Oncology Dispensary, 443031 - Samara/RU
  • 2Head Doctor, Samara Oncology Center, 4430131 - Samara/RU



One of the most serious potential side effects of chemotherapy is neutropenia. Grade 3 and 4 neutropenia is especially problematic because of increased incidence of infections, hospitalization, antibiotic treatment, necessity to reduce therapy intensity. Dicarbamin is agent for the prevention of chemotherapy-induced neutropenia. We conducted an analysis of efficacy of Dicarbamin in patients during Docetaxel-based chemotherapy.

Materials and methods

Between May 2011 and February 2012, 76 patients with early breast cancer were treated with adjuvant DAC regimens (docetaxel 75 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 every 3 weeks). All patients were female. All patients were treated with these regimens without prophylactic growth factor support. 42 patients (244 cycles of chemotherapy) were given Dicarbamin 100 mg/day on day 5 before chemotherapy administration. Treatment with Dicarbamin continued for all treatment period. 34 patients of control group (202 cycles of chemotherapy) were not giver any prophylaxis of neutropenia. Neutropenia was evaluated with Common Toxicity Criteria, Version 3.0.


Median age was 48 (29 – 55). Grade 4 neutropenia was reported in 6 (14.2%) patients treated with Dicarbamin and in 11 (32.3%) patients treated without Dicarbamin. The beneficial effect of Dicarbamin was also demonstrated by a quick recovery of granulocytes levels than in controls. In 15 (35.7%) patients treated with Dicarbamin granulocytes levels were normal all period of chemotherapy. The dose intensity of chemotherapy was more in group with Dicarbamin prophylaxis. The toxicity of Dicarbamin was not observed.


Dicarbamin is an active agent for prophylaxis of neutropenia without specific toxicity.


All authors have declared no conflicts of interest.